Drug Profile
Research programme: M4 muscarinic acetylcholine receptor modulators - AstraZeneca/Vanderbilt University
Alternative Names: M4 positive allosteric modulators - AstraZeneca/Vanderbilt University; PAMs - AstraZeneca/Vanderbilt UniversityLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Vanderbilt University
- Developer AstraZeneca; Vanderbilt University
- Class
- Mechanism of Action Muscarinic M4 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psychiatric disorders; Psychotic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Psychiatric-disorders in United Kingdom
- 16 Jul 2016 No recent reports of development identified for research development in Psychotic-disorders in United Kingdom
- 14 Jan 2013 Early research in Brain disorders in United Kingdom (unspecified route)